High Blood Pressure Research Council of Australia |
||||||||
|
. |
||||||||
HBPRCA Email
Newsletter
October 2009
|
||||||||
|
. |
||||||||
Welcome Note from
Geoff Head
|
||||||||
|
ISH2012 – As
you are all aware, the HBPRCA will be hosting ISH2012 in Sydney, 30 September
– 3 October. As members of the HBPRCA, we would like you to advertise the
Congress, by downloading the slides and including them at the end of your
presentations. Please click here to download. ISH2010 – will
be in Vancouver on the 26th-30th September. PowerPoint slides
for this meeting are available here. 2009 Annual Scientific Meeting News Feature Article: Long-term risk of sustained
hypertension in white-coat or masked hypertension Ambulatory Blood
Pressure Monitoring (ABPM) Working Group Initiative |
||||||||
|
. |
||||||||
|
. |
||||||||
President’s Message from Stephen Harrap |
||||||||
|
This e-News contains many examples of
that support including the recent first successful visit of our Young
Investigator Michael De Silva to the High Blood Pressure Research Council of
the American Heart Association as well as the new category of membership that
allows young investigators to retain their HBPRCA membership at no cost while
they are undertaking postdoc study abroad. These are 2 great new initiatives
added to our existing BHS exchange arrangements. Remember also that we have negotiated an
exclusive agreement with the BHS that allows up to 10 of our members to
register and attend their September meeting. In the light of the
encouragement above, why not make the BHS part of your travel plans? The
meeting is held usually in either Oxford or Cambridge and it is a high
quality mix of clinical and basic science research. It makes a great base to
tour European labs and with venues like St John’s College, Cambridge this
year (see photos), who could ask for more?
St
John’s College, Cambridge BHS September 2009
Presidential
Friends, Stephen Harrap (HBPRCA) & Gordon McInnes (BHS), Cambridge
September 2009 Finally, you can read something about the
people behind our valued sponsors. This is a great opportunity to get to know
them personally and for our younger members their stories provide insights
into potential career directions. Happy reading and see you all in Sydney
in December. |
||||||||
|
. |
||||||||
2009 Annual Scientific Meeting News from Kate Denton and Markus Schlaich
|
||||||||
|
IMPORTANT: Don’t forget
that the meeting is being held from Tuesday 1st to Thursday 3rd
December this year The
meeting is shaping up and it looks like it is going to be well attended. The
abstracts are in and being ranked as we speak. We have had an excellent turn out for the meeting in Sydney,
with "115" abstracts submitted. Remember, our guest speakers are Dr
Frans Leenen (RD Wright), Prof Michael Cowley (Austin Doyle) and Dr Alex
Brown (Colin Johnston) and we can expect some interesting and thought
provoking presentations. You
should also check out the "Environmentally Influenced Cardiovascular
Disease: From the Fetus to the Adult" workshop program that has been
finalised and it will have appeal to a wide audience and attendance is expected
to be high. Finally,
we will be inviting ECR and students to again participate in judging the
poster presentations. Any members
interested in acting as mentors in this endeavour should contact Erin
O’Callaghan, our student member, who is helping to organise this event or
myself. Registration
and abstract submissions are now officially open on-line and via paper form. For information on
the meeting, please visit the website. |
||||||||
|
|
||||||||
|
|
Register now! 1 – 3 December 2009 Close of EB registrations Friday 23 October 2009 |
|||||||
|
. |
||||||||
Workshop News from Geoff Head
|
||||||||
|
ASM Workshop Tuesday 1st December 2009:
“Environmentally Influenced Cardiovascular Disease: From the Fetus to the
Adult” This
workshop held over a single day will attempt to bring together various streams
of research by scientists and clinicians involved in the environmental
influences leading to cardiovascular disease. The plan is for sessions
involving fetal programming, children's issues through to the adult with
attention to special areas of concern such as indigenous Australians. Session
topics Early
Life Programming of Cardiovascular Disease Adult
Obesity and Cardiovascular Disease
Implications
for Clinical Management Strategies We
have 24 exciting speakers for our ASM workshop on Tuesday the 1st December
including our international guest speaker Professor Kevin Grove who will
discuss "The effects of fetal lipotoxicity on programming of the
cardiovascular system in the nonhuman primate" Venue Crystal
Palace, 1 Olympic Drive, Milsons Point, New South Wales Registration
fee $66.00,
incl. GST (via the Meeting First website) Workshop
Dinner Curve
Restaurant, Vibe Hotel North Sydney ($55, incl. GST) Workshop Committee:
Geoff Head, Kate Denton, Markus Schlaich, Louise Burrell, James Armitage,
Mary Wlodek, Bruce Neal and Annemarie Hennessy |
||||||||
|
. |
||||||||
Student News
|
||||||||
Important message
to all graduate students who are members of the HBPRCA ***IT’S FREE***
Are you
a graduate student working in hypertension or a related field? As
the HBPRCA is affiliated with the International Society of Hypertension (ISH)
there is an incredible opportunity for you to become A
Research Fellow of the International Society of Hypertension AT NO COST! This
permits you to 1. Obtain copies of the
quarterly Society Newsletter, Hypertension News 2. Save on conference
registration fees 3. Enjoy broader
opportunities to build relationships and network with peers and develop your career
as a leader in your field 4. Have access to the full
ISH Membership List (over 800 members) 5. Be eligible to receive
or nominate candidates for the Biennial ISH Awards 6. Be exempt from paying
the annual ISH membership fee 7. Be able to indicate
your status as an ISH Research Fellow on your CV Please
make sure you checkout the fabulous new ISH website (http://www.ish-world.com/default.aspx?Graduate_Students). |
||||||||
|
. |
||||||||
Membership News from Doug
McKitrick
|
||||||||
|
Membership in the
HBPRCA continues to grow. The June membership report tabled at the August 19
Executive Committee meeting indicated that there are 271 current members of the
HBPRCA. By comparison, 5 years ago at the end of 2004, membership stood at
200. During the August 19
teleconference the Executive also endorsed a new membership category intended
to help our student members retain an affiliation with the HBPRCA and move
from student to ordinary membership. This new category, called Special
Circumstances Membership, is particularly aimed at students that have
completed their degrees in Australia and have moved overseas for additional
training. The description and conditions of Special Circumstances Membership are: This membership
category has been established for recent graduates moving from Student
Membership to full Ordinary Membership in the HBPRCA. In an instance where the Applicant has: 1.
completed a degree program and; 2.
is no longer considered eligible for Student
Membership and; 3.
has requested a temporary exemption from paying
membership fees The HBPRCA Executive: 1.
with the recognition that the exemption allows the
Applicant to retain an affiliation with the HBPRCA and; 2.
with the understanding that the Applicant will
become a full Ordinary Member on return to Australia may grant the
exemption and grant the Applicant Special Circumstances Membership on the
basis that the Applicant: 1.
is in the first 5 years after graduation from
the degree program 2.
is engaged in relevant career training in a
laboratory outside Australia With Special
Circumstances Membership the Applicant will be:
|
||||||||
|
. |
||||||||
Society Liaison News from Bruce
Neal
|
||||||||
|
The
United Kingdom The
British Hypertension Society has just held its Annual Meeting where we were
ably represented by Stephen Harrap who kindly took a day or France We
have now made the second awards for the Franco-Australian Exchange travel
grants. The winner from the five
applicants from the Australian side, Erin O’Callaghan, will be spending three
months working with Genevieve Nguyen at the College de France Center for
Interdisciplinary Research in Biology at INSERM. Erin's work will seek
to determine the distribution of the (pro) renin receptor in the
cardiovascular centres of the rat brain. In regard to our colleagues in
France, we have recently heard form Prof Xavier Jeunemaitre, the incoming
president of the French Society, that Pr Pathak Atul from Tolouse will be
visiting Australia between June and September next year. Professor Gavin Lambert
at the Baker Institute in Melbourne will be hosting. The United States of America Thanks
primarily to the sterling efforts of Stephen and his counterpart in the US,
Rhian Toyuz, we now have a new exchange program with the USA. It has
now been confirmed that a reciprocal arrangement with the US Council has been
developed. The winner of the AHA Goldblatt prize will be given the
opportunity to come to Australia, commencing at the 2010 ASM. From our
side, Michael De Silva recently made the trip to the 63rd High Blood Pressure
Research Conference in Chicago where he presented on "Defining the
Role(s) of Nox2-containing NADPH Oxidase in the Cerebral Circulation".
According to their President Rhian Touyz, it was a ‘fantastic presentation’
that did a lot to remind our friends in the US just what a high standard of
research and talented young people we have in Australia. Michael is currently
undertaking his doctoral studies at the Department of Pharmacology in Monash
University. Michael also visited two laboratories in the US during his visit
where he had additional opportunities to present and receive feedback on his
doctoral research program. Michael will report on this in the December issue
of the e-News. |
||||||||
|
. |
||||||||
Corporate Liaison News from Louise Burrell
|
||||||||
|
In
the interests of strengthening ties between our sponsors and our members of
the High Blood Pressure Research Council of Australia, we are providing an opportunity
for the representatives of our sponsors to be better known through an article
in HBPRCA eNews. We have asked the representatives of sponsors if they would
like to write something about themselves. We had in mind a personal
perspective - something perhaps about their position and responsibilities in
the company and how they achieved the position, in terms of training and
career decisions. We think this information would be of particular interest
to our younger members who are facing career decisions themselves and would
be interested to hear those from people who have made successful choices
along the way. Our
members would also be interested in views on the challenges and exciting
developments that you see in the blood pressure field now and over the 5 to
10 years. We have sent out the requests and hope to publish as many of these
vignettes as possible before our December Annual Scientific Meeting. The
increase in profile will result in greater recognition of the
representatives, their company and better interaction around the exhibition
stands and other events. If
anyone has misplaced the request, or did not receive an invite but is
interested in writing such a personal piece then simply let Prof Geoff Head
know by email and he can advise you of the timelines and other details as
necessary. All
the very best and many thanks for your ongoing support of HBPRCA. Sponsor Profiles JLM Accutek Healthcare – Barbara
Iliopoulos My name is Barbara Iliopoulos, and I am employed by JLM Accutek
Healthcare. I am employed as the Business Development Manager for the
Diagnostic Cardiology Division, and my responsibilities are very unique and
quite diverse.
My journey has been challenging and
extremely rewarding. I have completed a Bachelor of Biomedical Science
Degree, a Masters in Business Administration and a Cardiac Technician
qualification to ensure that I can support all facets of my role. A burning
desire to succeed, a thirst for ongoing learning and personal development and
a passion for my chosen field have been the key attributes to my success. Novartis
– Ira Alvarez Ira Alvarez has been with Novartis since August last year and is the Cardiovascular Senior Product Manager. Her primary focus is the portfolio of anti-hypertensive medicines and ensuring they are accessible to both patients and practitioners, to achieve better health outcomes. Prior to joining Novartis, Ira spent 6 years with Merck Sharpe & Dohme performing roles in various capacities between Sales and Marketing across a range of therapeutic areas including cardiovascular, osteoporosis and respiratory. Before Ira joined the pharmaceutical industry, she spent 6 years helping patients as a physiotherapist, primarily with a sports or spinal injury, both in the public and private setting. sanofi-aventis australia – Robert
Buenaventura I am a physician by training and was in clinical practice focusing on
mental health and psychogeriatrics for about 10 years then I got invol The main challenge I see with the management of hypertension is
patient adherence to an appropriate treatment regime. Patient support
programmes (that espouse a healthy lifestyle and improved treatment
compliance) and the advent of new therapies in recent years (including fixed-dose
combinations) are two key approaches to the patient's success in reaching
target blood pressure goal. With major treatment guidelines being planned for
revision in the near future, we will see more emphasis on individualised
treatment of hypertension and more consideration placed on co-morbid
conditions. These show that hypertension management remains to be a very
dynamic field. The photo above was taken during our
internal celebration of World Hypertension Day last May. I am located on the
left end, wearing glasses and a tie. I'm with the members of our Karvea Brand
Team and our special guest for the day, comedian Jono Coleman. |
||||||||
|
. |
||||||||
Feature Article: Long-term risk of sustained hypertension in white-coat or masked hypertension |
||||||||
|
Michele
Bombelli, Guido Grassi, Roberto Sega, Giuseppe Mancia, Clinica Medica,
Ospedale S Gerardo, University Milan Bicocca, Monza (Milan ), Italy No conclusive
evidence exists as to whether isolated office hypertension or white coat
hypertension (WCH) and masked hypertension (MHT), ie the conditions in which,
respectively, only office or out-of-office blood pressure (BP) is elevated,
are clinically innocent or associated with an increased cardiovascular (CV)
risk. 1 This is because in WCH and MHT longitudinal studies have not always
documented a greater CV risk2. We addressed this issue using the data of the
PAMELA study, by evaluating whether, compared with the “true” normotension,
ie the condition in which both office and out-of-office BP are normal, WCH
and MHT are associated with an increased rate of development of “sustained”
hypertension (SHT), ie the condition in which both office and out-of-office
BP are elevated. A peculiar aspect of the study was that out-of-office BP was
measured both at home and over 24 hours, which allowed us to obtain 2
separate identifications of WCHT and MHT. Methods The
methods of the PAMELA study has been reported in details elsewhere3. Briefly,
3200 individuals were randomly selected from the white residents of Monza (a
town near Milan, Italy), to be representative of its residents for sex, age
(25 to 74 years), according to the criteria used by the World Health Organization
Monitoring Diseases Project4 conducted in the same geographic area. Data were
collected in 2051 subjects (64% of the original sample), and survivors were
contacted 10 years later to be re-examined. Between 1990 and 1992,
participants were invited to the outpatient sector of the local hospital
(Ospedale San Gerardo) in the morning of a working and underwent a number of
measurements and collection of information, the ones relevant for the present
analysis are as follows: (1) 3 sphygmomanometric BP measurements; (2) a
24-hour (morning-to-morning) ambulatory BP monitoring through a validated
oscillometric device (SpaceLabs 90207)
with the BP readings set at 20-minute intervals; (3) 2 home BP
measurements (at 7 AM and 7 PM) through a validated semiautomatic device
(model HP 5331, Phillips); (4) plasma glucose and lipid profile from venous
blood; (5) body mass index (body weight in kilograms divided by the square of
the height in meters); (6) information on other CV risk factors, major
diseases, and drug treatment. The same data were collected from 2001 to 2002.
Care was taken to keep the data collection procedure identical in the 2
occasions. In each individual office, home and 24-hour BP values were
averaged separately for the 1990–1992 and 2001–2002 data collection periods.
WCHT was diagnosed when, at the first examination, subjects showed an office
BP Results Of the
2051 subjects seen at the first examination, 157 died in the subsequent 10
years. A total of 482 subjects refused to participate or could not be
selected. Thus, a full set of data was obtained in 1412 subjects, including
individuals with SHT at the first examination, which were not considered for
further analysis. Entry age, male prevalence, body mass index, serum
cholesterol, serum triglycerides and plasma glucose were greater in
individuals with WCHT or MHT than in those with true normotension both when
these conditions were identified by office versus ambulatory and by office
versus home BP. The incidence of new-onset SHT was markedly greater in
subjects with WCHT and MHT than in true normotensive individuals both when
the groups were identified by office versus ambulatory and by office versus
home BP (figure 1).
Fig 1.
Mean percentage of individuals SHT based on office/24 hour (top) or
office/home (bottom) in subjects with WCHT, MHT, and true normotension (NT)
at entry. **P<0.0001
refers to the statistical significance between groups. Compared
with true normotension, the age- and sex-adjusted risks of
developing SHT were significantly increased in subjects with WCHT and MHT (OR
2.51, CI 1.79-3.54 for WCHT and 3.81, CI 2.57- 5.64 for MHT, based on
office/24 Hour BP; OR 1.78, CI 1.44-2.22 for WCHT and 1.67, CI 1.31-2.12 for
MHT, based on Office/Home BP, p< .0001), with no significant difference in
the increased risk between these 2 conditions (P=0.372 for office versus
ambulatory BP and P=0.398
for office versus home BP). This was also the case when separate
calculations were made of the subgroups without any
antihypertensive treatment (OR 3.25, CI 2.08-5.07 for WCHT and 3.69, CI
2.17-6.28 for MHT, based on office/24 Hour BP, p<.0001; OR 1.65, CI
1.27-2.15 for WCHT and 1.62, CI 1.20-2.21 for MHT, based on Office/Home BP,
p< .005), or those reporting use of antihypertensive drugs at
the first or the second examination (WCHT based on office versus
24-hour BP: 1.30, p=0.370;
WCHT based on office versus home BP: 2.26, P=0.009; MHT based on office versus 24-hour BP:
1.73, P=0.005; MHT based on
office versus home BP: 1.63, P=0.020). Office, home, and 24-hour BP values all independently
predicted the development of SHT, together with an independent and
usually less important contribution of age and metabolic
variables, eg, serum glucose and body mass index. There was, on
the other hand, no independent predictive value for use of
antihypertensive drugs, lipid profile, smoking habit, and sex in
the development of SHT. This was the case also for the presence of
1 or 2 out-of-office BP normalities in WCHT or 1 of 2
out-of-office BP elevations in MHT. Discussion Our
study shows that the percentage of subjects who develop SHT over a
relatively long time interval (10 years) is greater in individuals
who originally had WCHT or MHT than in true normotensive
individuals. It further shows that this is the case regardless of
whether the definitions of these different BP states are based on
office versus ambulatory or on office versus home BP values. The
greater choice of new-onset SHT exhibited by WCHT and MHT is by no
means marginal, because the age- and sex-adjusted risks were
almost doubled and more than tripled when these conditions were
diagnosed, respectively, by office versus home and office versus
ambulatory BP. Because the incidence of CV fatal and nonfatal
events and mortality is greater in the presence of SHT than when
only the in-office or out-of-office BP value is increased7 these
results provide a strong argument against the clinical
"innocence" of these conditions. A number of subjects
were on antihypertensive drug treatment, which could have made it
more difficult to reach the BP value defining office or out-of-office
BP elevation and prevented a precise determination of the
"natural" progression to SHT. It should be emphasized,
however, that antihypertensive drugs were more likely to be
administered in subjects with WCHT or MHT, which means that, if
anything, drug treatment might have led to an underestimation of
the actual increase in the risk of developing SHT in these 2
conditions. Furthermore, and more importantly, antihypertensive
drug treatment was not found to be an independent predictor of
new-onset SHT in the multivariate analysis that explored the
determinants of this phenomenon. Furthermore, the increment in the
risk of developing SHT in WCHT and MHT remained substantially
unaltered when calculations excluded subjects reporting an
antihypertensive drug assumption, and its size was similar in
untreated and treated individuals. The most significant predictors of
new-onset SHT were the BP values at entry, an expected finding
because it is obvious that the higher the initial BP the greater
the chance over the years to reach the cutoff BP value separating
normotension from HT. However, this does not entirely explain our
results, because the independent determinants of new-onset SHT
included metabolic variables. References 1.
Messerli
FH, Cotiga D. Masked hypertension and white-coat hypertension: therapeutic
navigation between scylla and charybdis. J Am Coll Cardiol. 2005; 46: 516–517 2.
Verdecchia
P, Angeli F, Gattobigio R, Borgioni C, Castellani C, Sardone M, Reboldi G.
The clinical significance of white-coat and masked hypertension. Blood Press
Monit. 2007; 12: 387–389 3.
Ambulatory
blood pressure normalcy: the PAMELA Study. Cesana G, De Vito G, Ferrario M,
Libretti A, Mancia G, Mocarelli P, Sega R, Valagussa F, Zanchetti A. J
Hypertens Suppl. 1991 Dec;9(3):S17-23 4.
WHO-MONICA
Project Principal Investigators. The World Health Organization Monica
Project: a major international collaboration. J Clin Epidemiol. 1998; 41:
105–114 5.
Ambulatory
blood pressure normality: results from the PAMELA study. Mancia G, Sega R,
Bravi C, De Vito G, Valagussa F, Cesana G, Zanchetti A. J Hypertens. 1995
Dec;13(12 Pt 1):1377-90 6.
Mancia
G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G,
Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A,
Schmieder RE, Boudier HA, Zanchetti A, for the ESH-ESC Task Force on the
Management of Arterial Hypertension. 2007 guidelines for the management of
arterial hypertension: the Task Force for the Management of Arterial
Hypertension of the European Society of Hypertension (ESH) and of the
European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105–1187 7.
Mancia
G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality
associated with selective and combined elevation in office, home, and
ambulatory blood pressure. Hypertension. 2006; 47: 846–853. |
||||||||
|
. |
||||||||
Ambulatory Blood Pressure Monitoring (ABPM) Working Group Initiative
|
||||||||
|
Members: Geoff Head,
Susie Mihailidou, Karen Duggan, Alexandra Bune, James Sharman, Arduino
Mangoni, Peter Howe, Narelle Berry, Diane Cowley, Michael Stowasser, Lawrie
Beilin, Jonathan Hodgson, John Chalmers, Carla Morey, Mark Nelson, Mark
Brown, Barry McGrath and John Ludbrook The aim of this
working group was to develop a clinical research collaborative to provide
sufficient data to derive a robust algorithm, which can link ambulatory blood
pressure monitoring (ABPM) (24hr average or awake average) readings to clinic
blood pressure (BP). So far we are pleased to have received contributions
from 11 research centres from 6 states totally over 8000 subjects with
clinical and ambulatory values. The
results from the study have been presented at the European Society of
Hypertension meeting in Milan in June. The main findings were that
at each clinic DBP and SBP target, predicted levels of day ABPM were quite
similar (within 1 mmHg). This contrasts with the PAMELA study, which showed
much lower ABPM values compared to clinic readings, which were measured by
doctors. We have now included over 1600 physician measured
clinic BP from 4 centres, which gave values much higher than the main
data set. The predicted ABPM values closely matched the PAMELA study
findings. We are very
pleased to announce that the 17-author manuscript has been finalised and
submitted to a journal. We are also pleased to have received endorsement from
the National Heart Foundation for this project, and have just received
confirmation that our findings will be included in a new revision of the
guidelines for ambulatory monitoring. We have also submitted an abstract to
the council meeting in December, which compares the differences between
physician and trained staff measurements of clinic blood pressure. Thank you to everyone
who contributed to this project so readily and constructively. |
||||||||
|
. |
||||||||
Upcoming Meetings
|
||||||||
|
Cardiology at the Frontier Symposium at VCCRI http://www.victorchang.edu.au/research/HomeandNews.cfm?cid=289 We would hereby
like to announce the 11th Victor Chang Cardiac Research Institute/St
Vincent’s Hospital International Symposium. Please see the attached
flyer and information sheet for further information. We look forward to
seeing you there.
Richard Harvey
(VCCRI) & Eugene Kotlyar (St. Vincent’s Hospital) The 23rd Scientific Meeting of the International Society of Hypertension
Recently we
sent you information on the 23rd Scientific Meeting of the
International Society of Hypertension (ISH 2010) and asked that you make your
members aware of this important meeting. We are pleased to announce that the ISH
2010 CALL FOR ABSTRACTS IS NOW OPEN. We have done this to permit
individuals from countries that need a longer time to obtain permission from
their institution and/or to obtain a visa to attend the meeting. The deadline
for submission is consistent with previous ISH meetings. Complete guidelines,
instructions on how to submit an abstract, and topic categories can be found
on the ISH 2010 website at www.VancouverHypertension2010.com.
The target audience includes Basic Scientists, Clinicians (Cardiology,
Endocrinology, General Medicine, Neurology, Nephrology, Primary Care
Physicians, Nurses, and Nutritionists), and Population Health and Public
Policy specialists and is inclusive of all individuals interested in
cardiovascular health. 8th Asian-Pacific
Congress of Hypertension 2011
(8th APCH 2011)
24
- 27 November 2011 Taipei
International Convention Center (TICC), Taiwan Official
website has launched! http://www.apch2011.tw/ It is my great
honour to share with you the exciting information that the 8th Asian-Pacific
Congress of Hypertension 2011 (8th APCH 2011) will be held in Taipei
International Convention Center (TICC), from November 24th (Thu) to November
27th (Sun), 2011! APCH is a
rapidly developing and most attractive scientific activity in the
Asia-Pacific area and has been held every two years since 1999. It is one of
the most important international Hypertension-related events held in this
region, which was first gathering in Indonesia (1999), and the participants
of 7th APCH 2009 in Malaysia had reached more than 1,600. APCH is authorized
by Asian Pacific Society of Hypertension (APSH), which is a confederation of
national societies of hypertension, and has been advancing the scientific
understanding of hypertension and improving the treatment of hypertension and
related vascular disorders in the community. It is a great honour that the
Taiwan Hypertension Society is appointed to host the 8th APCH at 2011. At 8th APCH
2011, in order to attract more physicians’ participation, it’s our great
pleasure to announce the Congress will be in conjunction with the Taiwan
Society of Internal Medicine and the 3rd World Congress on Ningen Dock
together making this EVENT better than ever. Therefore, we are expecting
totally more than 7,000 experts around the world, with the majority coming
from China, Japan and Korea, will attend the Congress. All the experts are
going to share and exchange their advanced knowledge and precious
experiences. We believe it will be a marvellous chance to grade up their
professional for all our colleagues and friends in the field of Hypertension.
Taking this
wonderful opportunity of a world union, we sincerely invite you to join us at
the Congress. With your support and participation, we will make this Congress
ever more successful! With open arms
and warm regards, we look forward to welcoming to Taipei in November 2011. Yours truly, Ming-Fong
Chen, MD, PhD Chairman, 8th
Asian-Pacific Congress of Hypertension 2011 President,
Taiwan Hypertension Society President,
Taiwan Society of Internal Medicine |
||||||||
|
. |
||||||||
|
HBPRCA would like to acknowledge the support of
the following companies: Corporate members
Corporate Sponsors
|
||||||||
|
. |
||||||||
|
. |
||||||||
|
Meetings in 2009 |
||||||||
|
||||||||
|
. |
||||||||
|
Meetings in 2010 |
||||||||
|
||||||||
|
. |
||||||||
|
Meetings in 2011 |
||||||||
|
||||||||
|
. |
||||||||
|
HBPRCA Secretariat
Athina Patti at Meetings First 4/184 Main Street LILYDALE VIC 3140 Phone +61 3 9739 7697 Fax +61 3 9739 7076 |
||||||||
